MiRus, LLC

MiRus is a medical device company developing proprietary implants and procedural solutions leveraging its proprietary Molybdenum-Rhenium (MoRe®) alloy technology. The company focuses on cardiovascular and orthopedic applications with an integrated platform spanning pre-operative, intra-operative, and post-operative solutions. MiRus' core technology, MoRe®, represents over 15 years of R&D and offers advantages over traditional medical materials (titanium, cobalt chromium) including smaller implant profiles, improved durability, enhanced biocompatibility, and significantly lower metal ion release. The company's cardiovascular portfolio includes the Siegel™ Transcatheter Aortic Valve (TAVR) system, currently in the STAR randomized controlled trial for symptomatic severe aortic stenosis. The orthopedic portfolio includes the IO™ Expandable Wedge Osteotomy System (FDA 510(k) cleared February 2026) and the EUROPA™ Posterior Cervical Fusion System (recipient of FDA New Technology Add-on Payment, NTAP). MiRus is headquartered in Marietta, Georgia, and was founded by experienced entrepreneurs with a track record of developing disruptive medical technologies. The company maintains an active clinical development program with multi-center trials and regulatory engagement with the FDA.